The Most Favored Nation (MFN) drug pricing policy is gaining momentum in the United States. While the policy’s breadth of implementation is still unclear, pharmaceutical manufacturers must be ready ...
Half of the experts, members of the Cornell Health Policy Insight Panel, indicated MFN pricing would substantially reduce net US drug prices, while half disagreed or were uncertain about the effects.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results